Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
Date:3/4/2013

CHESTERBROOK, Pa., March 4, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Cowen and Company 33rd Annual Global Healthcare Conference to be held March 4-6, 2013 at the Marriott Copley Place in Boston. Mr. Adrian Adams , Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 11:20 a.m. ET on Wednesday, March 6, 2013.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on March 6, 2013. To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for ninety days after the event.   

About Auxilium
Auxilium is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S.  GlaxoSmithKline LLC co- promotes Testim with Auxilium in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA on November 6, 2012 and has been accepted for standard review with a PDUFA date of September 6, 2013. Additionally, collagenase clostridium histolyticum ("CCH") is in phase II of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase II of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium is also developing a high concentration testosterone gel product. Auxilium also has rights to pursue additional indications for CCH.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission (the "SEC") on February 26, 2013. While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so. Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov. There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

For More Information, Contact:

Contacts:
James E. Fickenscher /CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900 
jfickenscher@auxilium.com

William Q. Sargent Jr. / VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900 
wsargent@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces Issuance of $350.0 Million of 1.50% Convertible Senior Notes Due 2018
2. Auxilium Pharmaceuticals, Inc. Announces Pricing of $325.0 Million of 1.50% Convertible Senior Notes Due 2018
3. Auxilium Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Due 2018
4. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals to Announce Third Quarter 2012 Results and Conduct Conference Call on Wednesday, November 7, 2012
6. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
7. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
10. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
11. Auxilium Pharmaceuticals to Announce First Quarter 2012 Results and Conduct Conference Call on Thursday, May 10, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... PUNE, India , May 25, 2016 ... "Medical Animation Market by Type (3D, 2D, 4D), by ... Patient Education), by End User (Medical Device Manufacturers, Hospitals/ ... report studies the global Medical Animation Market for the ... expected to reach USD 301.3 Million by 2021 from ...
(Date:5/25/2016)... , May 25, 2016  Zymo Research ... for their new reference materials that help researchers ... sample collection to analyses. The rapid growth of ... for researchers to have standard methods to improve ... generated. Biases inherently exist at every step of ...
(Date:5/25/2016)... , May 25, 2016 As ... Expo earlier this month, the numbers and momentum of ... to climb into the billions, more research and development ... 4th Edition State of Legal Marijuana Markets Report  from ... data-analysis firm, much of the increase in sector is ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 2016 , ... With a team of certified experts, Validation ... from its GMP accreditation, Validation Center is also a registered authority of the ... staff. , Validation Center is ISO17025 accredited and only offers its clients the ...
(Date:5/26/2016)... ... May 26, 2016 , ... W.S. Badger Co. Inc ., the ... a 2016 When Work Works Award for its use of effective workplace strategies to ... Work Works project administered by the Families and Work Institute (FWI) and the Society ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... in intellectual property (IP) to its specialty academic programs. , Answering to the ... college’s existing certificate programs in health law, and environmental and land use law. ...
(Date:5/26/2016)... ... 26, 2016 , ... The Woodlands at John Knox Village , Florida’s ... care for living and healing, celebrated its grand opening, today. The Woodlands at John ... provided by Empowered Staff. , “This is an incredibly fulfilling time for John Knox ...
(Date:5/26/2016)... New Hampshire (PRWEB) , ... May 26, 2016 , ... ... which are designed, engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. ... to provide reliable monitoring solutions trusted by government agencies, including NASA. , In ...
Breaking Medicine News(10 mins):